Image-Guided Brachytherapy a Comparison Between 192Ir and 60Co Sources in Carcinoma Uterine Cervix.

Abstract

Introduction: Combination of external beam radiotherapy (EBRT) and High Dose Rate (HDR) brachytherapy (BT) with concurrent chemotherapy (Cisplatin 40mg/m2/weekly) is the standard treatment of approach for the carcinoma of uterine cervix. In this study for image based HDR brachytherapy of intracavitary both 192Ir and 60Co sources were used for dosimetry and the dose distribution compared between point doses and volume doses as per the recommendation of ICRU89 and GEC-ESTRO on 3D image based planning. The dosimetry and clinical outcome will decide decisionmaking on choice of radionuclide for HDR brachytherapy of cervix in addition to economic reason.

Materials and methods: The Study conducted for 27 patients of cancer cervix stage IIB or IIIB with vaginal involvement limited to the upper third of vagina. All patients underwent concurrent chemoradiation Cisplatin 40mg/m2 weekly throughout EBRT by 3D conformal therapy 46Gy in 23# followed by two fractions of HDR brachytherapy with 9Gy/1Fr. Post implants 3mm slice selection of pelvic CT scans performed with ring applicator in place followed by T2 weighted paracorpal or paracoronal section of MRI imaging. The solid ring applicator (AL13017000) from library used for applicator reconstruction. Initially all plan calculated with TG-43 formalism using 192Ir radionuclide (Varian, GammaMed HDR Plus source) and then modelled 60Co radionuclide (Eckert < Ziegler BEBIG GmbH, Co0. A86) used for dose computation. ICRU89 recommended points and volumes of targets and OARs evaluated and compared.

Results: The study concludes that 60Co based point-A, BICRU and RICRU doses showed a comparable result with that of 192Ir HDR source based dosimetry. The volume based criterion for the target such as GTV, CTVHR, CTVIR for D90, D98, V150%and V200% are all within 5% dose level comparing two sources.

Conclusion: 60Co a viable alternate to 192Ir by taking into consideration frequency of source exchange and cost reserve with comparable dosimetry.